CV6-168 is a novel first-in-class DNA Uracilation agent that targets the enzyme dUTPase. When CV6-168 is used in combination with widely-used classes of cancer drugs including thymidylate synthase (TS) inhibitors and immuno-oncology drugs, uracil replaces thymine during cancer cell DNA replication, inducing the widespread uracilation of tumor DNA.
The unique mechanism of action of DNA uracilation induces cancer cell death while simultaneously stimulating innate immune signalling and establishing a pro-inflammatory environment.
DNA uracilation is novel mechanism of action that has demonstrated effectiveness and safety in appropriate in vitro and animal models with no added toxicity with drug combinations.
CV6-168, has completed pre-clinical development and is entering a Phase 1 clinical trial in 2023.
